Expanding the PsA Armamentarium

Expanding the PsA Armamentarium

GRAPPA Treatment Recommendations for Psoriatic Arthritis

Controlled Trials of DMARDs in Psoriatic Arthritis

Anti-TNF Therapies in PsAACR and PASI Responses

Anti-TNFs in PsAOther Outcomes

Current RA Therapies: Can They Be Used in PsA?

Abatacept in PsAACR and PASI Responses at 169 Days

Emerging Therapies for PsA

Emerging Therapies for PsA (cont)

T-Cell Differentiation Pathways

IL-23 and Resident T Cells Promote Enthesitis and Osteoproliferation

Ustekinumab Inhibits IL-12 and IL-23 by Targeting the p40 Subunit

PSUMMIT 1: Ustekinumab (IL-12/23i) in Psoriatic Arthritis

ACR20/50/70 Responders at Week 24

PSUMMIT2Efficacy of Ustekinumab in Psoriatic Arthritis at

24 Weeks

Change From Baseline in Modified Total vdH-S Score at 24 Weeks

TH17 CellsElevated in Patients With Psoriatic

Arthritis

Psoriatic Arthritis Synoviocytes Express High Levels of IL-17RA

IL-17 Inhibitors in Development for PsA

Efficacy of IL-17 Inhibitors in Plaque Psoriasis

BrodalumabACR Responses at 24 Weeks

Mean Change in DAS28 to 52 WeeksObserved Analysis

Mean Change From Baseline in Dactylitis and Enthesitis

Observed Analysis

IL-6 Cell Types and Biologic Activities

Cytokine Signaling Pathways

ApremilastPDE4 inhibitor

PALACE 1Apremilast in PsA

Efficacy of Tofacitinib in Psoriasis

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)